The Longest Living Patient Supported With Left Ventricular Assist Device (14 Years).

Autor:	Hallberg Kristensen A; From the Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden., Svenarud P; Department of Cardiac Surgery, Karolinska University Hospital, Stockholm, Sweden.; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden., Lund LH; From the Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.; Department of Medicine, Karolinska Institutet, Stockholm, Sweden., Najjar E; From the Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.; Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Jazyk:	angličtina
Zdroj:	ASAIO journal (American Society for Artificial Internal Organs : 1992) [ASAIO J] 2024 Oct 01; Vol. 70 (10), pp. e147-e149. Date of Electronic Publication: 2024 Sep 26.
DOI:	10.1097/MAT.0000000000002184
Abstrakt:	Left ventricular assist devices (LVADs) improve survival and reduce symptoms in patients with advanced heart failure; however, the longer-term durability of LVADs remains uncertain especially with older-generation devices. In this case report, we describe the clinical course of a patient who has been successfully treated with the same HeartMate II LVAD for 14 years, the longest published and still ongoing LVAD support with the same originally implanted device. Competing Interests: E.N. acknowledges speaker’s honoraria from Novartis, AstraZeneca, Boehringer Ingelheim, and Bayer, with no direct disclosures relevant to the current study. Similarly, L.H.L. has no direct disclosures associated with the present work. However, his unrelated disclosures include research grants from AstraZeneca and Boston Scientific, as well as consulting or speaker’s honoraria from Novartis, AstraZeneca, Bayer, St Jude, Medtronic, Vifor Pharma, and Abbott. The other authors have no conflicts of interest to report. (Copyright © ASAIO 2024.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu